Nanosonics is a leader in infection prevention solutions, largely due to its trophon ultrasound probe disinfection systems. Operating a razor-and-blade business model, it profits from both equipment sales and high-margin recurring revenues from product consumables. As the largest market for Nanosonics, North America provides significant opportunities for expansion, especially into new segments like endoscope cleaning. Strategic developments, such as new product launches and geographic expansion, hold promise for sustained growth. Despite current high valuations, execution on new initiatives will be crucial.

Nanosonics Limited (NAN.AX) Investment Analysis

1. Executive Summary

Nanosonics Limited is an Australian medical technology company specializing in infection prevention solutions, most notably the trophon ultrasound probe disinfection systemwisesheets.io. The company’s razor-and-blade business model centers on selling trophon units (capital equipment) and generating high-margin recurring revenue from associated disinfectant consumables and service contractsnanosonics.com. This model has made Nanosonics a global leader in automated high-level disinfection for ultrasound probesnanosonics.com. As of FY2024, the installed base of trophon units exceeded 34,700 units worldwidenanosonics.comnanosonics.com, with the primary market being North America (~90% of revenue)nanosonics.com. The company is expanding into new segments of infection control: it has developed CORIS – a novel endoscope reprocessing system currently under FDA review – and is leveraging partnerships to broaden its product portfolio (e.g. distributing Ecolab’s Soluscope TEE probe disinfectors)nanosonics.comnanosonics.com. Overall, Nanosonics’ strong recurring revenue stream, debt-free balance sheet, and focus on critical healthcare needs position it well for long-term growth, though its valuation reflects high growth expectations and execution will be key.

2. Business Drivers & Strategic Overview

Revenue Drivers: Nanosonics generates revenue from two main sources: (1) Capital sales of trophon units (expanding the installed base in hospitals and clinics), and (2) Recurring revenues from consumables (disinfectant cartridges, cleaning kits) and service contracts for those units. Recurring consumables/service now comprise ~72% of revenue (A$121.8M in FY2024) and grew 9% in FY2024 even as capital sales were subduednanosonics.com. This high proportion of recurring revenue provides stability and visibility, as each trophon unit generates ongoing demand for disinfectant consumables with every ultrasound procedure. The installed base grew 7% in FY2024 (adding 2,340 units) despite a slow first half, and by Dec 2024 reached ~35,840 unitsnanosonics.com, underpinning future consumables revenue growth. Trophon unit sales are driven by both new customer adoption and an upgrade cycle: over 9,000 older trophon EPR units (the first-generation model) are now >7 years old and potential upgrade targetsgrowthgauge.com.augrowthgauge.com.au. Indeed, in FY2024 Nanosonics sold 1,510 upgrade units as customers migrated to the newer trophon2, and upgrade volumes accelerated +44% in 2H FY2024 vs 1Hnanosonics.comnanosonics.com. This replacement cycle will continue to be a revenue driver in coming years as early-generation units age, especially in North America where adoption began earliest.

Geographic & Partnership Strategy: North America (USA & Canada) is Nanosonics’ largest market with ~30,390 units installed (about half of the estimated 60,000-unit total addressable market for trophon in that region)nanosonics.comnanosonics.com. Growth in North America comes from both penetrating new customers (many hospitals still do not use trophon in all relevant departments) and expanding usage in existing accountsnanosonics.com. After transitioning to a direct sales model in North America (phasing out a prior distribution partnership with GE Healthcare), Nanosonics now benefits from direct customer relationships and additional service revenuegrowthgauge.com.au. In other regions, Nanosonics employs hybrids of direct sales and distributors: for example, it markets directly in Australia/New Zealand and the UK/Ireland, while partnering with distributors like Ecolab in parts of Europe and the Middle Eastnanosonics.comnanosonics.com. In Europe (installed base ~2,300 units), Nanosonics is prioritizing key markets (UK, Germany, France) and recently got trophon on major procurement frameworks, helping drive 37% revenue growth in EMEA in 1H FY2025nanosonics.comnanosonics.com. In Asia-Pacific, Australia/NZ is a mature market (~70% penetrated) while Japan and other Asian countries are early-stage opportunities. Nanosonics is investing in Japan by working with medical bodies to establish local disinfection guidelines and demonstrate the need for trophon – early adopter sales in Japan did tick up in H1 FY2025 as awareness growsnanosonics.com.

R&D Pipeline and New Products: A cornerstone of Nanosonics’ strategy is reinvesting in R&D to broaden its infection prevention portfolionanosonics.comnanosonics.com. The flagship development is CORIS – a first-of-its-kind automated endoscope cleaning system designed to address the critical unmet need of effective lumen cleaning in flexible endoscopesnanosonics.comnanosonics.com. CORIS has completed clinical in-use studies and a de novo regulatory application was submitted to the U.S. FDA in April 2024nanosonics.com. The FDA review is ongoing, with Nanosonics recently responding to agency queries, and the company targeting a first commercial launch by Q1 FY2026 (July–Sept 2025) assuming clearancenanosonics.com. The strategic rationale is significant: there are over 60 million flexible endoscope procedures annually in major Western marketsnanosonics.com, and existing reprocessing methods are laborious and sometimes inadequate, as evidenced by numerous infection outbreaks linked to endoscopes. CORIS aims to offer a validated, automated solution for cleaning endoscopes, potentially tapping into a large new market adjacent to Nanosonics’ ultrasound niche. Beyond CORIS, Nanosonics’ R&D team is working on incremental innovations in its ultrasound disinfection franchise (e.g. connectivity solutions like AuditPro compliance software, next-gen device features)nanosonics.com and evaluating other instrument decontamination opportunities. Importantly, Nanosonics has developed deep expertise in biofilm science – understanding and removing biofilms in medical devices – which underpins its competitive advantage in developing effective infection control technologiesnanosonics.comnanosonics.com.

Competitive Advantages: Nanosonics enjoys a first-mover advantage and a strong reputation in its niche. The trophon device is considered the gold standard for automated high-level disinfection of ultrasound probes in many markets, offering a safer and more standardized alternative to manual disinfection with toxic chemicalsmorningstar.com. Trophon is protected by patented technology (e.g. sonicated hydrogen peroxide mist) and has been integrated into infection control guidelines in various countries. Its large installed base and established relationships with hospitals form a high barrier to entry for new competitors. Moreover, the recurring consumables model yields customer lock-in and high gross margins (~78%)nanosonics.com, enabling Nanosonics to fund R&D and stay ahead. Nanosonics also actively engages in educating the market and shaping standards (for example, working with professional bodies to endorse routine high-level disinfection of probes), which helps drive adoptionnanosonics.comnanosonics.com. That said, competition does exist: in ultrasound probe disinfection, alternatives include UV-based devices (e.g. Germitec’s systems) and chemical wipes (e.g. Tristel’s products), and large sterilization companies like STERIS and Ecolab offer related infection control solutionsemergenresearch.comgrandviewresearch.com. Nanosonics’ strategy to maintain its lead is continuous innovation (e.g. launching trophon2 and connectivity tools) and expanding its product range (e.g. CORIS) to address adjacent needs, making it more of a platform provider in instrument reprocessing.

Partnerships and Expansion: Partnerships play a tactical role in Nanosonics’ growth. The prior distribution alliance with GE in North America helped quickly build a base, and the subsequent shift to direct sales improved margins and opened new revenue streams (service contracts)growthgauge.com.au. In EMEA, Nanosonics partners with Ecolab for distribution in some markets and has an agreement to distribute Ecolab’s Soluscope TEE disinfectors in the UK/Ireland, broadening Nanosonics’ catalog to cover disinfection of transesophageal echocardiography probes (a niche not served by trophon)nanosonics.com. This complementary product selling indicates Nanosonics’ intent to be a one-stop provider for ultrasound probe hygiene. Additionally, Nanosonics’ healthy cash reserves enable potential M&A: management has explicitly stated interest in acquisitive growth in the medical instrument reprocessing sector, and recently hired dedicated personnel to scout opportunitiesnanosonics.com. Any bolt-on acquisition (for instance, a company with complementary technology or customer base) could accelerate international expansion or product diversification. Geographically, Nanosonics plans to deepen penetration in its existing markets (particularly Europe and Japan) by investing in local infrastructure and regulatory efforts. With cash of A$144.5M and no debt as of Dec 2024nanosonics.com, the company has ample capacity to fund expansion initiatives organically and inorganically.

3. Financial Performance & Valuation

Recent Financial Performance (FY2024): Nanosonics reported FY2024 (year ended 30 June 2024) revenue of A$170.0 million, a modest 2% increase over FY2023 (flat in constant currency)nanosonics.com. This tepid growth was due to a slowdown in capital sales early in the year: hospitals, constrained by inflation-driven budget pressures, delayed purchasing new trophon units and upgradesnanosonics.com. Indeed, capital revenue fell 11% to ~A$48M for the full year, but was offset by a 9% rise in consumables and service revenue to A$121.8Mnanosonics.com. Profitability in FY2024 was lower than the prior year as Nanosonics continued to invest heavily in growth initiatives. Gross profit margin held strong at 77.9% (vs 78.7% in FY2023)nanosonics.com despite a one-off H2 manufacturing slowdown to burn off excess inventorynanosonics.comnanosonics.com. Operating expenses grew ~10% to A$125.6M, reflecting increased R&D (including all CORIS development costs) and one-off implementation costs for a new ERP systemnanosonics.comnanosonics.com. Consequently, EBIT (operating profit before tax) declined to A$13.0M, down 40% from A$21.6M in FY2023nanosonics.comnanosonics.com. With virtually no income tax expense (due to R&D incentives and timing differences), net profit after tax was ~A$13M, a ~35% drop from the prior year’s A$19.9M. EPS correspondingly fell to around 4.0 cents per share in FY2024 (vs ~6.4¢ in FY2023)intelligentinvestor.com.au.

Latest Performance (FY2025 to date): The first half of FY2025 (6 months to 31 Dec 2024) showed a strong rebound. 1H FY2025 revenue was A$93.6M, up 18% year-on-yearnanosonics.com, driven by a recovery in capital sales (A$24.4M, +11%) and robust growth in consumables/service (+20%)nanosonics.com. Notably, hospital purchasing activity picked up in late 2024 as capital budgets reset, and trophon upgrade orders accelerated. Nanosonics’ operating leverage improved: 1H FY25 EBIT was A$8.7M, a nearly 3× increase from A$3.0M in 1H FY24nanosonics.com. Net profit for the half was A$9.8M vs A$6.2M pcp, and EPS for H1 came in at 3.22¢, up from 2.04¢marketscreener.com. Buoyed by this momentum, management upgraded its full-year revenue growth guidance to +11–14% (from +8–12% previously)nanosonics.com, implying FY2025 revenue in the high $180Ms. Gross margin also normalized back above 78% in H1 FY25 as production volumes returned to normalnanosonics.com. With operating costs growing slower than revenue (+10% YoY)nanosonics.com, profitability is on track to exceed FY2024 levels. The company’s financial position remains very strong: as of Dec 31, 2024 it held A$144.5M in cash with zero debtnanosonics.com, and even after significant R&D spend it generated +A$13.8M free cash flow in the halfnanosonics.com.

Current Valuation Multiples: Nanosonics’ stock trades at premium multiples, reflecting investors’ high expectations for growth (especially from CORIS) and the quality of its recurring revenue model. At a share price around A$4.40 (June 2025), the company’s trailing P/E is in the range of 80–95× FY2024 earningsintelligentinvestor.com.auinvesting.com – a very high figure due to the temporary earnings dip in FY2024. On a forward basis, the P/E remains elevated; for instance, using consensus FY2025 EPS (~4.4¢) gives ~77× and using FY2026 EPS (~8.8¢) still ~38×intelligentinvestor.com.au. Other metrics likewise appear lofty: the enterprise value/sales is about 7–8× (i.e. >7x its annual revenue)investing.com, and EV/EBITDA is currently on the order of 40–50× (TTM basis), well above industry averages. These rich multiples price in substantial future growth and imply that Nanosonics is valued more like a high-growth healthcare software/tech company than a typical medtech device firm. It’s worth noting, however, that Nanosonics’ balance sheet strength (over $0.45 per share in cash, no debt) and high gross margins support higher valuation ratios to some extent. Additionally, as earnings scale up in coming years (with operating leverage and new product revenue), these multiples could moderate rapidly – for example, if net profit doubles by FY2026 as some forecasts anticipate, the forward P/E would compress accordingly. Nevertheless, by conventional measures NAN appears expensive, with a Price/Sales near 7.4× versus ~2–3× for medtech peersinvesting.com, and investors are clearly paying a premium for Nanosonics’ market leadership and growth runway. Any shortfall in execution or growth could lead to significant valuation contraction – a key consideration for investors.

(Table: Key Financials)

(All financials in AUD. FY2023 and FY2024 are full-year; 1H FY2025 is half-year vs prior half. EV/EBITDA is estimated trailing 12-month. Sources: Company reports and filings.)

4. Risk Assessment & Macroeconomic Considerations

Nanosonics faces several risks that investors should monitor:

• Regulatory & Product Development Risk: A significant portion of Nanosonics’ future growth hinges on successful regulatory approval and commercialization of new products like CORIS. Any delays or hurdles in the FDA process could push back the launch and revenue from CORIS. As of mid-2025, the CORIS system is still under FDA de novo review (with some follow-up questions being addressed)nanosonics.com. There is no guarantee of approval on the expected timeline; additional data requests or a lengthy review could occur given the novelty of the technology. Moreover, even after approval, CORIS will likely require further clearances (510(k) expansions) to cover the full range of endoscope typesgrowthgauge.com.au, potentially elongating the pathway to tap the entire addressable market. This means R&D spending will remain high and any unforeseen technical challenges could impact Nanosonics’ roadmap. Outside CORIS, any future products (or even next-gen trophon iterations) carry typical development risks: technical feasibility, clinical efficacy, and market adoption uncertainty. Regulatory compliance in multiple jurisdictions (FDA, TGA, CE Mark in EU, etc.) is a continuous process; changes in standards or requirements (for example, more stringent disinfection regulations) could be a double-edged sword – creating demand but also imposing compliance costs.

• Competitive & Market Adoption Risks: While Nanosonics currently enjoys a dominant position in ultrasound probe disinfection, competition is emerging in both its current and target markets. In ultrasound disinfection, competitors like Germitec (France) offer UV-based devices, and UK-based Tristel markets high-level disinfectant wipes as a lower-cost alternativeemergenresearch.com. Large healthcare sterilization companies (e.g. STERIS, Ecolab, ASP) are also active in infection control and could introduce or acquire competing solutionsemergenresearch.com. A key risk is that hospitals could choose these alternative methods if they are cheaper or more convenient, especially in price-sensitive markets – though it’s worth noting Nanosonics’ automated approach has significant safety and efficacy advantages over manual or UV methods, which helps retain customers. In the upcoming endoscope reprocessing arena, Nanosonics will be entering a field traditionally served by established makers of automated endoscope reprocessors (AERs) and high-level disinfectants (e.g. Olympus, Getinge/Cantel, STERIS). These incumbents have deep relationships with hospitals and might respond aggressively (through pricing or new product features) if CORIS threatens their market share. Convincing infection control departments to adopt a new system may take time; entrenched practices and even skepticism can slow uptake. Market adoption risk is pronounced in regions like Japan and parts of Europe where guidelines for probe disinfection are not yet firmly in place – Nanosonics must invest in education and guideline development to create demandnanosonics.com. If these efforts stall, growth in those regions could disappoint.

• Macroeconomic & Healthcare Capital Spending Cycles: Nanosonics’ sales are influenced by the capital expenditure cycles of hospitals and clinics. In FY2024, the company saw firsthand how macroeconomic factors can hit sales: high inflation and rising interest rates pressured hospital budgets, causing delays in capital purchases of trophon unitsnanosonics.com. If economic conditions tighten or if healthcare providers face funding constraints (e.g. government healthcare budget cuts, recession impacts), hospitals may defer or reduce spending on new equipment, which would directly slow Nanosonics’ capital sales. Conversely, an improving economic or financing environment (or specific funding programs for infection control) can unlock pent-up demand – but this is largely outside the company’s control. The current global backdrop of higher interest rates makes capital equipment ROI thresholds tougher, potentially elongating sales cycles. Nanosonics partially mitigates this by emphasizing the safety and cost-benefit of its solution (preventing costly infections), but budget timing remains a swing factor. Another macro consideration is healthcare utilization rates – e.g. if there is a downturn in elective ultrasound procedures or endoscopies (due to pandemic waves or economic slowdown impacting patient volumes), consumables usage could dip. Thus far, procedure volumes have been on an upswing post-COVID, benefiting consumables revenue, but this is a variable to watch.

• Foreign Exchange (FX) Exposure: Nanosonics reports in AUD but earns the bulk of its revenue in other currencies, especially USD (North America) and EUR/GBP (Europe). For example, the average AUD/USD rate in FY2024 was 0.66nanosonics.com, and movements in FX can impact reported results. A weakening AUD generally boosts Nanosonics’ reported revenue and profit (as foreign sales translate into more AUD), which provided a slight tailwind in FY2024 (constant-currency growth was 0% vs 2% reported)nanosonics.comnanosonics.com. However, the AUD can be volatile; a significant strengthening of AUD against USD/EUR would reduce reported growth and could compress margins if not hedged. The company does not appear to heavily hedge currencies, so FX gains/losses flow through (indeed, a $1.3M FX gain in H1 FY25 helped boost profit)nanosonics.com. Investors should be aware that exchange rate fluctuations may introduce noise into Nanosonics’ financial performance independent of operational results.

• Operational & Execution Risks: As a manufacturing and distribution business, Nanosonics faces typical operational risks – supply chain disruptions, production scalability, and quality control. The company manufactures its devices and consumables (the exact supply chain is undisclosed, but likely a mix of in-house and outsourced components). Any shortages of key materials or components (e.g. specialized electronics or chemical ingredients) could slow production. In FY2024, Nanosonics proactively slowed manufacturing in one half to manage inventorynanosonics.comnanosonics.com; while this was deliberate, it shows that balancing production with demand is an ongoing task. If CORIS is approved, scaling up production for a complex new device will be a challenge – ensuring adequate capacity and service capability for a new product launch is critical. Another risk is concentration: to date, Nanosonics’ revenue depends overwhelmingly on one product family (trophon). Any issue affecting trophon – such as a major device recall, a safety scare, or a superior technology emerging – could have outsized impact. Nanosonics has an excellent quality track record so far, but as the installed base grows, they must maintain strong field support to handle any technical problems efficiently (they have been building out their service infrastructure, particularly after taking it in-house from GE). The company is also implementing a new enterprise resource planning (ERP) system by FY2025nanosonics.com; large IT projects carry risk of disruptions during transition if not managed well. On the sales execution front, there’s reliance on key personnel and distribution partners: for instance, Nanosonics’ direct salesforce in the U.S. is pivotal – any turnover or inefficiency there could slow growth, and similarly distributor performance in other regions (e.g. if partners like Ecolab do not prioritize trophon sales) could be a bottleneck. Lastly, M&A execution is a risk if the company pursues acquisitions – overpaying or failing to integrate an acquired business could destroy value, though management has been conservative so far and is merely exploring optionsnanosonics.com.

In summary, Nanosonics’ key risks span regulatory outcomes, competitive dynamics, macroeconomic factors, FX, and operational execution. The company’s strong fundamentals (cash-rich, market leader with recurring revenue) help buffer some risks – for example, its cash provides resilience against downturns and fuel for addressing issues. Also, infection control tends to be a non-discretionary priority (hospitals can only postpone it so much given patient safety imperatives), which somewhat insulates demand. Nonetheless, investors should monitor hospital capex trends, competitor actions (e.g. new product launches by others), the progress of CORIS through regulatory hurdles, and the company’s ability to convert its pipeline into tangible growth. Any major deviation in these areas could impact the investment thesis.

5. 5-Year Scenario Analysis

We examine three plausible scenarios for Nanosonics’ business over the next five years (through 2030), outlining the assumptions, financial trajectory, and resulting share price for each case. These scenarios are grounded in Nanosonics’ fundamentals – such as market opportunities and operational leverage – rather than simply extrapolating the current stock price. All projections are in AUD. (No dividends are assumed, consistent with company practice of reinvesting earnings.)

High Case (Bull)

Key Assumptions: In the bullish scenario, Nanosonics capitalizes on most of its opportunities. Trophon adoption accelerates globally, fueled by heightened infection control awareness and supportive regulations. We assume the company consistently places ~3,000+ new trophon units per year (including conversions of remaining hospitals and expansion into under-penetrated regions like Asia), which, along with a continuing upgrade cycle, grows the installed base at ~10% CAGR. By 2030, the installed base could approach ~60,000 units (nearly full penetration of the >60k global TAM for ultrasound probe disinfectors)nanosonics.com. Recurring consumables revenue scales in tandem, and usage per unit may rise modestly as procedure volumes grow. CORIS is a major success: assume FDA approval comes on time (FY2026) and the product gains rapid adoption in key markets. Given the ~60 million annual endoscope procedures across Western marketsnanosonics.com, even capturing 5–10% of this procedural volume by 2030 would drive substantial revenue. In this bull case, CORIS could become a second growth engine contributing hundreds of units sold and significant consumable revenue (cleaning cartridges, etc.) by year 5. We also assume Nanosonics executes well on any ancillary products or partnerships (e.g. TEE probe disinfectors, or perhaps an acquisition of a complementary product) adding incremental revenue streams. Operationally, strong volume growth combined with high gross margins yields improving operating leverage: OPEX grows much slower than revenue (given R&D on CORIS tapers off post-launch), resulting in expanding EBIT margins. By FY2030, net profit margins could approach 20%+ in this scenario (versus ~8% in FY2024). We also assume the company retains its cash-rich, debt-free status, and perhaps uses some cash for share buybacks if it generates excess capital.

Financial Outlook: Under these assumptions, Nanosonics’ revenue might roughly double over 5 years. For example, by FY2029–30 revenue could reach on the order of $350–400M (vs $170M in FY2024), with trophon sales and consumables still growing and CORIS adding perhaps $100M+ annually by then (if, say, a few thousand CORIS units are installed across major hospitals). EBITDA/EBIT would grow faster as margins expand, potentially reaching $80–100M EBIT by 2030. EPS could climb dramatically – with modest share count growth, EPS might be in the ~$0.20–0.30 range in five years under these bullish conditions. Importantly, the market is likely to still award a growth premium: even in 2030, if Nanosonics is seen as a global infection control leader with ongoing growth, it could trade at a P/E of say 30–35× (or higher). We also add the value of its cash reserves (which would accumulate further). In sum, this scenario yields a much larger market cap.

Valuation & Share Price: By 2030, applying a P/E ~35 to a hypothetical $0.25 EPS gives a stock price around $8.75, and adding net cash per share ($0.50+) could justify a ~$9+ share price. We present one possible share price trajectory below, showing a steady climb as fundamentals strengthen:

High Case: Assumes accelerating growth (revenue doubling in 5 yrs, EPS ~$0.25 by 2030). Price path is illustrative, reaching ~$9+ in 5 years (~110% upside from current).

Base Case (Moderate Growth)

Key Assumptions: The base case envisions Nanosonics executing its strategy reasonably well, but without any massive outperformance or surprises. Trophon continues to grow at a healthy, if not spectacular, pace: assume ~2,500 new units placed per year on average (in line with management’s near-term expectationsgrowthgauge.com.au), plus steady upgrades. This yields mid-single-digit growth in installed base (perhaps reaching ~50,000 units globally by 2030). Recurring consumables revenue grows proportional to installed base and slightly higher in some years as more customers sign on to service contracts. We assume CORIS is approved around mid-2025 to 2026 and starts contributing from FY2026 onward, but adoption is gradual. Perhaps a few hundred CORIS units are installed in the first couple of years, mostly in leading U.S. and European hospitals, and ramp-up is tempered by the need to educate the market and integrate into hospital workflows. By 2030, CORIS might capture a modest single-digit percentage of the endoscope reprocessing market – still a valuable addition, but not dominating. Together, these drivers yield solid revenue growth in the low teens percentage annually for the next few years, tapering to high-single digits later (as trophon approaches saturation in core markets). Margins: In this scenario, Nanosonics’ profitability improves gradually. Gross margin stays ~77–80% (as efficiency gains offset pricing pressure). Operating expenses grow ~6–8% annually (continued R&D on pipeline and global sales expansion), a bit slower than revenue, allowing EBIT margin to rise toward mid-teens by 2030. We assume no major hiccups: the competitive environment remains manageable, and any new products or partnerships are incremental. Nanosonics likely still has a sizable net cash balance, perhaps investing some in expansion or small tuck-in acquisitions but no transformative M&A.

Financial Outlook: Under these moderate assumptions, revenue might grow at ~10% CAGR, reaching perhaps ~$275–300M by 2030. (For instance, if FY2025 is ~$190M, and growth steps down from ~12% early to ~8% later, you end up in that range.) Trophon would still be the bulk of business, with CORIS adding maybe ~$40–60M/year by the fifth year (assuming a few hundred systems and associated consumables in use). Net profit would improve significantly from the current ~$13M – possibly reaching on the order of $50–60M by FY2030 if things go to plan. That would equate to an EPS around $0.16–0.20 in five years. In terms of valuation multiples, by 2030 Nanosonics might be viewed as a more mature company but still growth-oriented (especially if CORIS is picking up steam). A P/E in the mid-20s could be reasonable for the base case (assuming growth prospects beyond 2030 moderate).

Valuation & Share Price: If EPS in 5 years is, say, ~$0.18 and the market assigns a 25× P/E, the implied share price would be ~$4.50. However, we must also consider that in the interim the stock would likely appreciate and then flatten as it grows into its valuation. Starting from $4.40 today, we might expect an initial rise as earnings improve and CORIS launch approaches, then a leveling off. An illustrative share price path for the base case could be:

Base Case: Assumes sustained moderate growth (revenue ~1.6× in 5 years, EPS ~$0.18 by 2030). Price reaches around $6 in 5 years (~35% upside), with a smoother upward trajectory.

Low Case (Bear)

Key Assumptions: In the bearish scenario, several challenges constrain Nanosonics’ growth. Trophon adoption slows considerably – perhaps low single-digit growth in installed base – due to factors such as intensifying competition (hospitals opting for alternative disinfection methods or competitors undercutting on price), and near-saturation in key markets. For instance, in this scenario Nanosonics might struggle to place much more than ~1,500 units per year, only partially offsetting replacements of retiring units. Some existing customers might extend the life of old trophon units rather than upgrading on Nanosonics’ preferred timetable, further dampening capital sales. Consumables usage could also plateau if ultrasound procedure growth slows or if some customers lapse in compliance. On the CORIS front, assume a setback: perhaps regulatory approval is delayed significantly (e.g. requiring additional trials, pushing launch out by a year or more), or the product hits commercial challenges (could be higher cost or slower-than-expected uptake due to entrenched AER systems). In this low case, CORIS contributes minimal revenue in the next 5 years – it might still launch, but adoption is tepid and adds little to the top line by 2030. We also imagine competitive pressure on pricing: Nanosonics might have to offer discounts or more value-add (reducing effective pricing) to defend market share, which could erode margins. Additionally, macro factors might not cooperate – persistent hospital budget constraints or a recession could periodically dent sales. Margins: With revenue underperforming, Nanosonics might maintain high R&D and sales investment (to try and spur growth), keeping operating expenses high relative to sales. EBIT margins could remain in the single digits. The company’s cash would dwindle more slowly (since it’s not losing money, just not growing fast), but the opportunity cost of that cash would rise if returns are low. The company might even consider returning some cash to shareholders or making a risky acquisition out of frustration, which in this scenario we’ll assume doesn’t create much value.

Financial Outlook: In a stagnation scenario, revenue growth might average only ~5% or less. By FY2030, revenue could be perhaps ~$220–230M (essentially only modestly above inflation from $170M today). Most of the growth would come from price adjustments or consumable price increases rather than volume. Net profit might improve only slightly or even oscillate if costs rise – for instance, net income could end up in the $20–30M range by 2030. EPS might then be on the order of $0.07–0.10 (not much higher than current ~4–5¢). In such a scenario, the market would likely compress Nanosonics’ valuation multiples dramatically, seeing it as an ex-growth or slow-growth company. A P/E in the low 20s or teens could be more appropriate, especially if broader market sentiment is cautious.

Valuation & Share Price: If by 2030 EPS is ~8 cents and growth prospects are minimal, a multiple of ~20× might apply, yielding a stock price around $1.60. Even adding cash per share, one might justify maybe $2 at best as fundamental value. The share price trajectory in this case would probably be weak: the stock could drift down as growth disappoints, with occasional bumps on speculative news that don’t sustain. An example share price path:

Low Case: Assumes substantial slowdown (revenue barely grows, CORIS contribution minimal). Price could erode to ~$2 over 5 years (−55% from current), reflecting multiple contraction and lack of earnings growth.

Probability-Weighted Outcome: We assign subjective probabilities to each scenario – Bull 20%, Base 60%, Bear 20% – reflecting our view that the most likely outcome is a moderate growth path, with an smaller chance of extreme upside or downside. Using these weights, the expected 5-year price comes out around $5.80–6.00 (roughly in line with the base case outcome). That implies a modest upside from the current ~$4.40, commensurate with steady execution but not without risks. It’s also worth noting that Nanosonics’ current valuation appears to price something between the base and bull case (given the high multiples), so any shortfall toward the bear case could cause a sharper stock correction. Conversely, if the company does skew toward the high case (e.g. CORIS truly booming), the stock could materially re-rate higher over time. Moderate Upside

6. Qualitative Scorecard

Below we rate Nanosonics on several qualitative factors key to its investment appeal, on a scale of 1 (poor) to 10 (excellent):

• Management Alignment (7/10): Management appears reasonably aligned with shareholders’ interests. CEO Michael Kavanagh has led the company for nearly a decade, overseeing its growth from an early-stage to a global player, and is invested in Nanosonics’ long-term success. Insiders have meaningful shareholdings (though the founder has left, current leadership and board members do hold equity). The company’s strategic decisions – such as opting for direct sales in the U.S., and reinvesting cash into R&D – suggest a focus on building long-term value rather than short-term profits. Governance is generally solid with an experienced board. One minor ding is that management has not yet returned any capital to shareholders (no dividend, limited buybacks) despite a large cash pile – but this is justifiable given growth opportunities. Overall, management’s incentives and actions seem aligned with driving sustainable growth.

• Revenue Quality (9/10): Nanosonics boasts high-quality revenue. Over 70% of total revenue is recurring in nature (consumables and service contracts)nanosonics.com, which provides a stable, predictable cash flow base. This razor-and-blade model means once a trophon unit is installed, it generates ongoing consumable demand with high customer switching costs (hospitals won’t abandon the device easily, and consumables are proprietary). Revenues are also diversified across thousands of end-users (no single customer dependency) and across geographies (North America, EMEA, APAC). Additionally, gross margins on revenue are very high (~78%nanosonics.com), indicating pricing power and value-add. The only drawbacks are that revenue is currently concentrated in one product category (ultrasound disinfection) and one region (~50% of units in the U.S.nanosonics.com), and it is subject to healthcare capital spending cycles. But the planned broadening into endoscopy and new markets will further enhance revenue quality in the future.

• Market Position (8/10): Nanosonics holds a strong market position as the de facto standard for automated ultrasound probe disinfection. It enjoys a near-monopoly in the installed base for this niche in large markets like the U.S., having ~50% penetration of the identified TAM in North Americananosonics.com and a growing presence elsewhere. The company’s technology is protected by patents and know-how (especially in microbiology and biofilm removalnanosonics.com), and it has built a significant lead over smaller competitors. Brand loyalty is high – trophon is often specifically named in infection control guidelines and tenders. That said, the market position is niche: Nanosonics is a mid-cap by global standards and operates in a specific segment of infection control. Larger firms with more resources (e.g. STERIS, Ecolab) are adjacent and could leverage their networks to compete if they chose, representing a latent threat. Also, Nanosonics is just entering the endoscope market, where it will not be incumbent. Still, in its established domain, its position is very robust and likely defensible.

• Growth Outlook (8/10): The growth outlook for Nanosonics is positive. In the near to medium term, the company has multiple growth drivers: continued trophon penetration (especially in emerging markets and lagging regions like Japan), an upgrade cycle that will drive replacement sales, and organic growth of consumables as the installed base and usage grow. The upcoming launch of CORIS in endoscope cleaning could unlock a transformational new market – success there would significantly boost the growth trajectory beyond just ultrasound. Furthermore, management’s openness to complementary acquisitions means there’s potential for inorganic growth. Analysts expect Nanosonics to accelerate earnings growth in FY2026 and beyondintelligentinvestor.com.au, reflecting these opportunities. We temper the score slightly because execution is not guaranteed – CORIS, while exciting, is unproven commercially, and macro factors (hospital budgets) could intermittently slow things. Also, growth rates may naturally moderate as trophon penetration gets higher. But overall, high-single to double-digit growth for the next 5+ years seems likely, which is excellent in the medtech space.

• Financial Health (10/10): Nanosonics’ financial health is excellent. The company has no debt and a substantial cash reserve (A$129.6M at June 2024, growing to $144.5M by Dec 2024)nanosonics.comnanosonics.com. Its business is cash-generative (even in FY2024, with soft earnings, free cash flow was $20M+nanosonics.com), and the recurring revenue model means operating cash flow is relatively resilient. The strong balance sheet provides a buffer against any unforeseen downturns and gives Nanosonics strategic flexibility (to invest in R&D, expand geographically, or make acquisitions). Key financial ratios are solid: current ratio is high (inventory is well-managed and much of revenue is collected promptly, sometimes upfront via service contracts), and with no leverage, there’s no solvency risk. The company’s prudent capital management (no dividend while in growth phase, no dilution except minor stock-based compensation) also contributes to health. In short, Nanosonics is in a very secure financial position with capacity to fund its growth plans internally.

• Business Viability (8/10): By business viability, we mean the long-term sustainability of Nanosonics’ business model and relevance. The company addresses a fundamental and growing need – infection prevention – which is not going away. In fact, as healthcare standards rise and patient safety regulations tighten, demand for automated disinfection should only increase. Nanosonics’ core technology (low-temperature high-level disinfection) is well-established and backed by science, and the company has proven it can adapt (e.g. updating trophon to new models, developing new products). We see minimal risk that the concept of high-level disinfection becomes obsolete; if anything, it may become more mandated. The viability risk could come from technological disruption – for example, if a radically new method of probe sterilization emerged that is superior (none is evident yet), or if ultrasound probes themselves change (e.g. disposable probe covers widely replacing need for disinfection, though that seems unlikely for intracavity probes due to imaging quality issues). Another angle is the single-product dependence: for now, Nanosonics is essentially “a one-trick pony” in business terms, which is usually a viability concern. However, the move into endoscope reprocessing and possibly other areas will diversify that. With its cash and R&D expertise, Nanosonics should be able to sustain its business model viability through innovation. We assign a high score, deducting a couple points mainly for the concentration risk and the need to prove multi-product success.

• Capital Allocation (7/10): Nanosonics’ capital allocation has been conservative and focused on growth. Positive aspects: the company has not engaged in value-destructive acquisitions or frivolous spending; instead, it has funneled capital into R&D, market development, and building its direct sales capabilities – uses that have clear strategic rationale. It also wisely retained earnings and raised capital when needed in the past to ensure a strong balance sheet, which now funds new initiatives debt-free. Management’s decision to hold a large cash buffer could be debated – on one hand, it provides safety and flexibility, on the other, it earns minimal return and could be seen as inefficient if not deployed. So far, the plan seems to be to use cash for opportunistic M&A or to accelerate CORIS production, which could yield high returns if done right. The company does not pay dividends (understandable for a growing tech-oriented firm) and has only modest share issuance (mostly for employee incentives). One concern is if they become too conservative – e.g. not investing enough or hoarding cash unnecessarily – but given the R&D pipeline, that’s not evident. If an acquisition is pursued, execution will be the true test of capital allocation skill. For now, we view Nanosonics’ capital deployment as prudent, if slightly cautious, hence a decent score.

• Analyst/Investor Sentiment (7/10): Market sentiment on Nanosonics is moderately positive but with some caution. The stock has attracted a premium valuation and a dedicated following among growth-oriented investors, reflecting confidence in its long-term story (CORIS, global expansion, etc.). Recent news has generally been met favorably – e.g. the FDA submission and clearance news in March 2025 saw shares jump to multi-year highsmarketscreener.com. Several analysts cover the stock and, as of early 2025, the consensus leaned towards “Hold” to mild “Buy”, with target prices around mid-$4s to low-$5stradingview.com, which is not far from the trading price. For instance, Morgans Financial upgraded NAN to Add (a buy-equivalent) in Feb 2025 with a $4.50 targetmarketscreener.com, and other analysts have inched targets upward after the strong half-year results. However, sentiment is tempered by the high valuation – some analysts likely see it as fully priced (or “priced for perfection”) and are waiting for evidence of CORIS success before turning more bullish. Short interest in the stock has generally been low, indicating no significant bearish sentiment, but the stock’s volatility around news suggests sentiment can swing. Overall, the market believes in Nanosonics’ quality, but expectations are also high, leading to a balanced sentiment score.

• Profitability (6/10): This score looks at current and near-term profitability. Nanosonics’ profitability metrics are a mixed bag. On the one hand, gross margins are excellent (~78%nanosonics.com) and the core trophon franchise is solidly profitable (management disclosed that the trophon business alone delivered $40.4M profit before tax in FY24, a 24% PBT marginnanosonics.com). On the other hand, overall earnings are modest relative to sales, with FY2024 net margin ~7.6% and ROE in single digits. Heavy reinvestment in R&D and SG&A has suppressed operating margins – which is acceptable for growth, but still means profitability is currently low in absolute terms (NPAT was only ~$13M on $170M revenue). Return on invested capital is likely middling at present given the large cash and ongoing expenses. The trajectory, however, is upward: 1H FY2025 saw margin improvement with EBIT margin ~11.6%nanosonics.com, and consensus expects EPS to grow strongly into FY2026intelligentinvestor.com.au which would boost profitability ratios. We give a slightly below-average score now, acknowledging the high potential for improvement. If we were scoring future potential profitability (once CORIS scales and OPEX growth slows), Nanosonics could score much higher. But for now, profitability is the one area where the company is under-earning relative to its valuation.

• Track Record (8/10): Nanosonics has an impressive track record overall. Since its first product launch a decade ago, the company has grown its revenue more than ten-foldgrowthgauge.com.au, achieved global market penetration, and continuously remained at the forefront of its niche. It has been EBITDA-profitable for many years, a notable achievement for a small Aussie medtech that heavily reinvests. Management has generally delivered on guidance (notable exception: the slow first half FY24, though that was largely due to external factors). The company successfully navigated the transition from distributor sales to direct sales in North America around 2020 – a period where some volatility in results occurred (FY2022 even saw a small loss due to one-off changesgrowthgauge.com.au), but the long-term outcome was positive, with better margins and control. They’ve also proven adept at expanding internationally in a thoughtful way (e.g. securing regulatory approvals and then gradually building presence). One slight blemish: the pace of new product introduction has been slow – trophon was launched in 2009, and more than a decade later CORIS is the first major new product. That indicates careful development, but also means the company has been reliant on one product for a long time. Nevertheless, their methodical R&D efforts now seem to be bearing fruit. Considering where Nanosonics started and where it is now – a profitable, globally recognized medtech – the track record is strong.

Overall Blended Score: 7.8/10 – Strong. Nanosonics scores highly on most qualitative dimensions: it has a solid management team, high-quality recurring revenues, a dominant market position in its niche, strong growth catalysts, and impeccable financial health. While its current profitability is modest and valuation is demanding, the company’s fundamental quality and execution history inspire confidence. In summary, Nanosonics appears to be a high-quality growth company in a compelling niche, albeit with execution risks to monitor. Strong

7. Conclusion & Investment Thesis

Investment Thesis: Nanosonics offers a unique combination of a defensive healthcare franchise (recurring revenue from a critical infection-control product) and embedded growth options (new markets and products like CORIS). The company’s trophon business provides a profitable and cash-generative foundation, underpinned by increasing awareness of infection risks and a trend toward stricter disinfection protocols globally. This core business alone still has room to grow – with roughly half of the addressable ultrasound market in North America penetrated and even less in other regions, Nanosonics can continue to expand its installed base and harvest recurring revenuesnanosonics.com. Meanwhile, the forthcoming CORIS endoscope cleaner represents a potential step-change: if successful, it opens a much larger revenue opportunity (the global endoscope reprocessing market is several times the size of the ultrasound segment) and could establish Nanosonics as a broader infection prevention platform company. The stock’s current valuation reflects optimism about these prospects, so the crux of the thesis is execution. An investor in NAN is betting that Nanosonics will (1) sustain its dominance in ultrasound disinfection – fending off any competitors and converting the remaining market – and (2) execute the CORIS launch effectively, proving to hospitals that its new technology can solve a major unmet need and achieving significant adoption over the next few years. If both play out, Nanosonics’ earnings could grow into the currently lofty valuation and then some, delivering strong returns.

Catalysts: Key catalysts on the horizon include: U.S. FDA clearance of CORIS (recently, in March 2025, the company announced it received de novo clearance from the FDAmarketscreener.com, a major de-risking event – the focus now shifts to commercialization timelines); the first commercial installations of CORIS (expected in FY2026) and feedback from early users – positive clinical outcomes or endorsements could accelerate uptake. Another catalyst is the expansion in Japan and other new markets – for instance, if Japan’s health authorities issue guidelines recommending high-level disinfection of ultrasound probes, that could unlock a wave of demand, and Nanosonics has been actively pursuing this via presenting clinical datananosonics.com. Financial performance will also drive sentiment: watch for revenue re-acceleration and margin improvement in FY2025–FY2026 – if Nanosonics meets or exceeds its ~11–14% growth guidance for FY2025nanosonics.com and shows evidence of operating leverage (as seen in 1H FY25), it will bolster confidence that the growth story is on track. Additionally, any strategic partnerships or acquisitions could be catalysts; for example, Nanosonics might partner with a major endoscope manufacturer or sterilization company to co-market CORIS, which would validate the product and speed adoption. On the M&A front, while nothing concrete has been announced, the company’s stated interest in acquisitions means an accretive deal (e.g. acquiring a complementary technology) could provide upside surprise.

Risks: On the flip side, the key risks to the thesis include those discussed in section 4: slower hospital capital spending, potential competition making inroads, or CORIS not meeting commercial expectations. If CORIS launch is delayed or if early uptake is weak, the market could sharply reassess Nanosonics’ growth trajectory. Similarly, if trophon sales falter (due to a new competitor or simply saturation), the core business might not produce enough growth to justify the high multiple. Investors should also watch gross margins and costs – a significant contraction in margin (perhaps from pricing pressure or cost inflation) could hurt profitability. Currency movements (especially AUD vs USD) can impact reported earnings as well. Lastly, the stock’s high valuation means it is sensitive to any disappointment: even small misses on quarterly/annual numbers or cautious outlook comments can trigger volatility.

Outlook and Valuation: Balancing these factors, our base case analysis suggests that Nanosonics’ current share price is baking in a continuation of solid growth. The probability-weighted scenario (section 5) yielded an expected price modestly above the current market price, indicating a reasonable but not spectacular return if the company executes to plan. In essence, Nanosonics is a long-term growth play in a niche of healthcare that is becoming increasingly important. For investors with a multi-year horizon and tolerance for above-average valuation metrics, Nanosonics offers exposure to this growth with a quality underpinning (strong balance sheet, proven product). The stock may not appear “cheap” by traditional metrics, but if one believes in the infection prevention megatrend and Nanosonics’ ability to lead it, the premium could be justified by many years of compounding returns. In the near term, news flow around CORIS and quarterly sales momentum will likely drive the stock’s direction. Over the longer term, if Nanosonics achieves something close to our bull case, today’s valuation will in hindsight look quite reasonable.

In conclusion, Nanosonics is a compelling growth story in healthcare tech, with a dominant core product and a promising new platform on the way. The company’s strengths (recurring revenue, innovation, financial stability) position it well, but investors should monitor execution on new initiatives and be mindful of the rich valuation. For those confident in management and the infection control theme, Nanosonics represents an attractive long-term investment, albeit one that requires patience and careful attention to risk factors. Positive Outlook

8. Technical Analysis, Price Action & Short-Term Outlook

Nanosonics’ share price has exhibited a strong upward trend over the past year, bolstered by improving fundamentals and positive news flow. The stock is up about 60% year-on-yearinvesting.com, and in March 2025 it hit a near two-year high following the FDA clearance announcement for CORISmarketscreener.com. This momentum pushed the price to an intraday peak around A$4.80–4.90. Since then, a period of consolidation has set in: as of early June 2025 the stock trades in the mid-$4s (~A$4.35–4.40), off its highs but still above key support levels. Notably, NAN remains comfortably above its long-term 200-day moving average (MA), which is around A$3.75–3.80asx.swingtradebot.com. Trading above the rising 200-day MA reflects that the broader uptrend is intact. However, the stock has slipped below its shorter-term averages (the 50-day MA is about A$4.66asx.swingtradebot.com), indicating some loss of near-term momentum after the post-news rally.

In technical terms, the recent price action can be described as a pullback or consolidation within a longer-term uptrend. The correction from ~$4.8 to ~$4.3 occurred on relatively modest volume (aside from the high volume days around the March news), suggesting it was more of a profit-taking and digestion of gains rather than a trend reversal. The relative strength index (RSI) and other oscillators cooled from overbought levels in March to more neutral readings by late May, which is healthy. The stock even received an ASX price query in May when it had a sharp move – management’s response indicated no undisclosed information, so likely general market rotation or technical trading caused the swingintelligentinvestor.com.au. Support is observed around the A$4.00 mark – this is a psychologically important round number and roughly where the 100-day MA residesasx.swingtradebot.com. Further support is at the 200-day MA (~A$3.7–3.8); coincidentally, that zone also aligns with the stock’s breakout level from late 2024, which should provide a strong floor barring a significant negative development. Resistance in the near term is the recent high region around $4.80–5.00; a decisive break above ~$5 on volume would be very bullish and potentially signal the next leg up.

Looking at trend indicators, the long-term trend is clearly up (the series of higher highs and higher lows since mid-2022 remains unbroken). The medium-term trend (3–6 months) is sideways-to-up: shares have been range-bound roughly between $4.0 and $4.8 in 2025, but maintaining an upward bias vs 2024 levels. Shorter-term, as noted, momentum has waned: the stock holds sell signals on the short-term moving averages crossover according to some technical servicesstockinvest.usstockinvest.us, meaning in the immediate term the path of least resistance might be sideways or a bit down. However, there are signs of consolidation rather than a sharp decline – for instance, on down days the volume has not spiked alarmingly, and the stock seems to be finding support in the low-$4s.

Volume and News Impacts: Volume has averaged about 1.0–1.1 million shares traded per day over the past 3 monthsinvesting.com, indicating decent liquidity for an ASX mid-cap. Volume spikes have correlated with news: the late-August 2024 earnings release, the January 2025 trading update, and the March FDA news all saw above-average volume and price gaps up. After those events, volume tapered off as the stock settled into its range. This suggests that catalyst-driven rallies are a feature – with the next potential catalyst being the full FY2025 results in Aug 2025 or any early commercial update on CORIS. Absent news, the stock may continue to trade in a range as investors await the next data point.

Short-Term Outlook: In the coming weeks to months, NAN’s stock is likely to be influenced by general market sentiment (particularly toward growth/healthcare stocks) and any incremental company updates. Technically, as long as it stays above the $4.00 support, the bullish structure is intact. A break below $4 could signal a deeper pullback (perhaps toward the mid-$3s), but that appears to have a low probability barring a market-wide sell-off or negative company news. On the upside, a rally back above the 50-day MA ($4.66) would indicate strengthening momentum; crossing $4.80 would confirm a bullish breakout from the consolidation. Given the current neutral momentum and lack of immediate scheduled catalysts, the base expectation is for the stock to oscillate within its recent range ($4.0–4.8) in the short term, with a slight upward bias if broader market trends are positive (since the fundamental news flow for NAN has been positive). Traders might find opportunities to buy on dips toward support and lighten near the upper end of the range. Long-term oriented investors may view any pullbacks as opportunities, provided the fundamental thesis is unchanged, since the long-term uptrend is still in place. In summary, the short-term technical picture is one of cautious optimism: the uptrend is intact but the stock is digesting gains, so a bit of patience may be required before the next sustained move. Uptrend Intact